SCHEMBL3016374

SCHEMBL3016374

O=S(=O)(c1ccc(Br)cc1)C1CCN(c2nc(Cc3cc(F)cc(F)c3)cs2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.37
RAB9A P51151 6/20 0.37
NPC1 O15118 5/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
HTR2A P28223 5/20 0.36
HTR2C P28335 4/20 0.36
KCNH2 Q12809 4/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
ALDH1A1 P00352 1/20 0.36
DRD2 P14416 2/20 0.34
GPR6 P46095 1/20 0.33
MAPT P10636 3/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
CYP2C19 P33261 1/20 0.33
MAPK1 P28482 2/20 0.33
LMNA P02545 1/20 0.33
DNM1L O00429 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019381 0.94 HTR2A (0.37) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL3020046 0.93 HTR2A (0.42) SMN1; SMN2RAB9ANPC1HTR2AHTR2C
SCHEMBL3013242 0.91 HTR2A (0.35) SMN1; SMN2RAB9ANPC1HTR2AHTR2C
SCHEMBL3013102 0.90 GBA1 (0.41) SMN1; SMN2RAB9ANPC1KMT2AHTR2A
SCHEMBL3015772 0.90 HTR2A (0.44) SMN1; SMN2RAB9ANPC1HTR2AHTR2C
SCHEMBL3017825 0.90 GPR6 (0.35) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL3000018 0.89 RAB9A (0.38) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL3015207 0.89 SMN1; SMN2 (0.36) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL3014535 0.88 DNM1L (0.38) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL3006919 0.88 ALDH1A1 (0.35) SMN1; SMN2RAB9ANPC1HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.